Celltrion, Incorporation operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Celltrion, Incorporation with three other
companies in this sector in South Korea:
Samsung Biologics Co Ltd
sales of 535.81 billion Korean Won [US$444.18 million]
of which 99%
was Antibody Drugs),
Green Cross Corporation
(1.33 trillion Korean Won [US$1.11 billion]
of which 86%
was Greencross), and
Celltrion HealthCare Co Ltd
(713.49 billion Korean Won [US$591.48 million]
of which 96%
was Goods Sales).
Celltrion, Incorporation reported sales of 982.07 billion Korean Won (US$814.14 million)
December of 2018.
increase of 3.5%
versus 2017, when the company's sales were 949.08 billion Korean Won.
Sales at Celltrion, Incorporation have increased during each of the previous five years
(and since 2013, sales have increased a total of 334%).
Sales of Chemical Business Division saw an increase
that was more than double the company's growth rate: sales were up
7.7% in 2018, from
129.53 billion Korean Won to 139.47 billion Korean Won.
Not all segments of Celltrion, Incorporation experienced an increase in sales in 2018:
sales of Other Segment fell 12.9% to 7.70 billion Korean Won.
(However, this segment's sales were only a very small portion of the company's overall sales).